Pharmacology

Cincinnati Business Courier Announces Gravity Diagnostics as Fast 55 Award Finalist

Friday, June 11, 2021 - 5:17pm

COVINGTON,Ky., June 11, 2021 /PRNewswire/ --Gravity Diagnostics has been chosen as a 2021 Fast 55 finalist by the Cincinnati Business Courier.

Key Points: 
  • COVINGTON,Ky., June 11, 2021 /PRNewswire/ --Gravity Diagnostics has been chosen as a 2021 Fast 55 finalist by the Cincinnati Business Courier.
  • The Fast 55 Award is granted to privately held companies in the region with the fastest growth in the past year.
  • Gravity Diagnostics is a CAP-accredited CLIA certified laboratory that offers testing in the areas ofCOVID-19, Upper Respiratory, Toxicology, Pharmacogenomics, Sexually Transmitted Infections, and Blood.
  • Gravity could not be more honored to be recognized as one of the fastest-growing companies in the Greater Cincinnati area," - Tony Remington, CEO, and Co-Founder of Gravity Diagnostics.

Trulieve Expands Patient Access with Latest Tampa Dispensary

Friday, June 11, 2021 - 1:00pm

The dispensary will be located next to the Citrus Park Town Center and helps meet Trulieve's goal of ensuring medical cannabis patients across Florida have safe, reliable access to the medications they rely on.

Key Points: 
  • The dispensary will be located next to the Citrus Park Town Center and helps meet Trulieve's goal of ensuring medical cannabis patients across Florida have safe, reliable access to the medications they rely on.
  • The facility joins four other Tampa dispensaries, as well as several more in nearby Clearwater, St. Petersburg, and Largo.
  • In honor of the Company's newest dispensary, all patients from those new to Trulieve to the dedicated Truliever community will be eligible for a 25% in-store discount at the new dispensary on opening day.
  • Trulieve also offers home delivery statewide for patients and convenient in-store pickup at each of its 83 dispensaries in Florida.

Innocan Pharma's Liposome Platform Technology Demonstrates a 7-Week Prolonged Release of CBD into Bloodstream in Recent Animal Study

Friday, June 11, 2021 - 8:00am

Innocan believes this result to be extremely encouraging, given the 24-hour maximum CBD presence in the bloodstream when administered through traditional channels.

Key Points: 
  • Innocan believes this result to be extremely encouraging, given the 24-hour maximum CBD presence in the bloodstream when administered through traditional channels.
  • This unique liposome platform technology may have a wide range of applications, such as epilepsy, pain relief, inflammation and central nervous system disorders.
  • Innocan Pharma is a pharmaceutical tech company that focuses on the development of several drug delivery platforms containing CBD.
  • The founders and officers of Innocan Israel each have commercially successful track records in the pharmaceutical and technology sectors in Israel and globally.

Pharmaceutical Executive® Unveils the 21st Annual Pharma 50

Thursday, June 10, 2021 - 4:52pm

Pharmaceutical Executive based rankings of the top 50 global biopharma leaders on companies' prescription drug sales.

Key Points: 
  • Pharmaceutical Executive based rankings of the top 50 global biopharma leaders on companies' prescription drug sales.
  • "With the end of the COVID-19 pandemic in sight, the Pharmaceutical Executive Pharma 50 list demonstrates the top sales performers that played a part in combating the public health crisis the industry has been facing," said Mike Hennessy Jr., president and CEO of MJH Life Sciences, parent company of Pharmaceutical Executive.
  • In addition to paying close attention to connected current trends, Pharmaceutical Executive based its rankings of the top 50 global biopharma leaders on the companies' full-year prescription drug sales in 2020.
  • Pharmaceutical Executive is a multimedia platform that offers news, opinions, analysis, features and executive profiles.

Japan Pharmaceutical Market Growth, Trends, COVID-19 Impact, and Forecasts 2021-2026 - ResearchAndMarkets.com

Thursday, June 10, 2021 - 3:25pm

The "Japan Pharmaceutical Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Japan Pharmaceutical Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)" report has been added to ResearchAndMarkets.com's offering.
  • Japan's pharmaceutical market has a strategic edge in its ability to make strong-quality pharmaceutical drugs and high-quality packaging technology.
  • Japan also has the greatest standard of quality assurance and quality control throughout the globe, as the Japanese pharmaceutical market aims to enhance the quality of pharmaceutical products across the globe.
  • Nevertheless, Japan's pharmaceutical market remains third largest market, behind the United States and China.

CASI Pharmaceuticals Announces Dosing Of First Patient Of CID-103 In Phase 1 Clinical Trial For Relapsed Or Refractory Multiple Myeloma

Thursday, June 10, 2021 - 12:00pm

The study is designed to assess the safety, tolerability, pharmacology and clinical activity of CID-103.

Key Points: 
  • The study is designed to assess the safety, tolerability, pharmacology and clinical activity of CID-103.
  • "We are excited to dose the first patient in the evaluation of CID-103," commented Wei-Wu He, Ph.D., CASI's Chairman and Chief Executive Officer.
  • This Phase 1 trial will generate valuable information and has the potential to provide early evidence of clinical activity in the treatment of multiple myeloma."
  • The Company's operations in China are conducted through its wholly-owned subsidiary, CASI Pharmaceuticals (China) Co., Ltd., which is located in Beijing, China.

Rapid Therapeutic Finalizes Lab Work on Pharmaceutical Formulas

Thursday, June 10, 2021 - 12:00pm

RTSL has developed three (3) proprietary pharmaceutical formulas, two (2) for cannabidiol (CBD) and one (1) for cannabigerol (CBG), to initially be used in Metered Dose Inhalers (MDI).

Key Points: 
  • RTSL has developed three (3) proprietary pharmaceutical formulas, two (2) for cannabidiol (CBD) and one (1) for cannabigerol (CBG), to initially be used in Metered Dose Inhalers (MDI).
  • RTSLs CEO, Donal R. Schmidt, Jr. stated, We initially set out to find an ultra-pure, unadulterated pharmaceutical grade CBD isolate to use in our MDI.
  • We also learned CBD isolate is not chemically compatible with metered dose inhalers without significant modifications in the manufacturing process.
  • In short, we were unsatisfied with any product we could source in the hemp space to meet our needs.

PLx Pharma Inc. to Present at Upcoming Healthcare Industry Conferences

Wednesday, June 9, 2021 - 9:30pm

It also reduces the risk of stomach erosions and ulcers, as compared to immediate-release aspirin, common in an acute setting.

Key Points: 
  • It also reduces the risk of stomach erosions and ulcers, as compared to immediate-release aspirin, common in an acute setting.
  • PLx Pharma Inc. is a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard drug delivery platform to provide more effective and safer products.
  • The PLxGuard drug delivery platform works by targeting the release of active pharmaceutical ingredients to various portions of the gastrointestinal (GI) tract.
  • To learn more aboutPLx Pharma Inc. and its pipeline, pleasevisit www.plxpharma.com .

Wilful Blindness, How a network of narcos, tycoons and CCP agents infiltrated the West by Sam Cooper

Wednesday, June 9, 2021 - 2:01pm

What these bombshell stories do not disclose, are the background revelations published in Sam Cooper's best selling new book, Wilful Blindness.

Key Points: 
  • What these bombshell stories do not disclose, are the background revelations published in Sam Cooper's best selling new book, Wilful Blindness.
  • Cooper's book reveals how Vancouver has become a high-tech hub for encryption companies used by transnational cartels and also espionage applications.
  • SkyChat, yet another encryption company run out of Vancouver and allegedly linked to nefarious actors, has also been fingered by international police.
  • Beijing is weaponizing fentanyl in diplomacy with the West, according to intelligence and law enforcement in Canada.

European Patent Office upholds Curadev's cyclodextrin patent for new composition of matter

Wednesday, June 9, 2021 - 12:39pm

SANDWICH, England, June 9, 2021 /PRNewswire/ -- Sulphobutyl ether -cyclodextrin (SBE--CD) is used as an excipient to improve the solubility and stability of a range of active pharmaceutical ingredients, prominent among which is the antifungal drug, voriconazole.Working with Professor Steve Wicks and his team at the University of Greenwich, Curadev developed a new method for producing sulphoalkyl ether -cyclodextrins.The method also enabled the production of SBE--CD with a high average degree of substitution (ADS), something which was not previously possible.This is particularly advantageous as it is thought that increasing the ADS of SBE--CD will decrease its toxicity.Curadev applied for and were granted a European patent on 18 April 2018 which protected both the method of producing SBE--CD and the novel SBE--CD compositionsper sehaving a high (ADS).

Key Points: 
  • SANDWICH, England, June 9, 2021 /PRNewswire/ -- Sulphobutyl ether -cyclodextrin (SBE--CD) is used as an excipient to improve the solubility and stability of a range of active pharmaceutical ingredients, prominent among which is the antifungal drug, voriconazole.Working with Professor Steve Wicks and his team at the University of Greenwich, Curadev developed a new method for producing sulphoalkyl ether -cyclodextrins.The method also enabled the production of SBE--CD with a high average degree of substitution (ADS), something which was not previously possible.This is particularly advantageous as it is thought that increasing the ADS of SBE--CD will decrease its toxicity.Curadev applied for and were granted a European patent on 18 April 2018 which protected both the method of producing SBE--CD and the novel SBE--CD compositionsper sehaving a high (ADS).
  • We are pleased to announce that Curadev successfully defended a challenge to the patent from Ligand Pharmaceuticals at an opposition hearing held by the European Patent Office and attended by representatives for both Curadev and Ligand on 18 May 2021.On receiving the EPO verdict, Dr. Anton Hutter, LLB, of Venner Shipley and Lead Counsel for Curadev, said, "This is an excellent result, and supports our view that Curadev have developed a truly inventive process and product."
  • To know more about Curadev, visit our website www.curadev.in